trending Market Intelligence /marketintelligence/en/news-insights/trending/9Cxxjpwj4PItD3YqvikjqA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

XBiotech starts tender offer to buy up to $420M of its common shares

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

XBiotech starts tender offer to buy up to $420M of its common shares

XBiotech Inc. started a tender offer to buy up to $420 million of its common shares at a price of between $30 and $33 apiece.

The Austin, Texas-based biopharmaceutical company said the offer will provide the company's shareholders the opportunity to obtain liquidity with respect to all or a portion of their stock in the company without disrupting XBiotech's stock price.

The offer is subject to certain terms and conditions. The tender offer will expire at 5 p.m., New York City time on Feb. 12 unless the offer is extended.

D.F. King & Co. Inc. will be information agent for the tender offer.

XBiotech develops therapies based on harnessing naturally occurring antibodies from patients with immunity to various diseases.

In December 2019, Johnson & Johnson acquired all rights to XBiotech's experimental anti-inflammatory antibody bermekimab in a $750 million deal. XBiotech was developing bermekimab as a potential treatment for different cancer types; diabetes; cardiovascular diseases; and skin disorders, including atopic dermatitis, or eczema, and hidradenitis suppurativa.